Medindia LOGIN REGISTER
Medindia
Advertisement

Perrigo Acquires Exclusive Sales and Distribution Rights to Allergy Drug Levocetirizine from Synthon

Tuesday, September 9, 2008 General News
Advertisement
ALLEGAN, Mich., Sept. 8 Perrigo Company (Nasdaq:PRGO; TASE) announced today that it has acquired the exclusive U.S. rights tosell and distribute Levocetirizine tablets, the generic version of UCB'sXyzal(R) tablets, from Synthon Pharmaceuticals, Inc. Synthon believes it has afirst to file ANDA application for the generic that can entitle it to 180 daysof generic exclusivity upon approval. Synthon and UCB are currently engagedin Paragraph IV/Hatch-Waxman litigation over the Synthon ANDA filing.
Advertisement

Xyzal(R) is indicated for the treatment of indoor and outdoor allergies.It is estimated that it has annual sales of approximately $200 million dollarsgrowing at 15% per year, according to data provided by Wolters, Kluwer.
Advertisement

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is a prime exampleof Perrigo's strategic focus on introducing new products which will makequality healthcare more affordable to American consumers. Given Perrigo'sunique model of leadership in both the over-the-counter and genericprescription businesses, we can leverage this first to file opportunitywhether the brand product stays behind the pharmacy counter or if it switchesto an over-the-counter status, a likely scenario."

Perrigo Company is a leading global healthcare supplier that develops,manufactures and distributes over-the-counter (OTC) and prescriptionpharmaceuticals, nutritional products, active pharmaceutical ingredients (API)and consumer products. The Company is the world's largest manufacturer of OTCpharmaceutical products for the store brand market. The Company's primarymarkets and locations of manufacturing facilities are the United States,Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet( http://www.perrigo.com ).

Synthon Pharmaceuticals, Inc., with its U.S. headquarters and laboratorieslocated in Research Triangle Park, North Carolina, markets generic drugs underits own name and through partnerships with other leading pharmaceuticalcompanies. Synthon currently holds several approved, or tentatively approved,drug applications and our pipeline contains more than a dozen products thatare expected to be filed with the FDA within the next few years. SynthonPharmaceuticals, Inc. is part of the Synthon group, a global privately heldspecialty pharma company with offices, laboratories and manufacturing sites inthe Netherlands, Spain, Czech Republic, Australia, Argentina, Chile and theUSA. Visit Synthon on the Internet ( http://www.synthon.com ).

Note: Certain statements in this press release are forward-lookingstatements within the meaning of Section 21E of the Securities Exchange Act of1934, as amended, and are subject to the safe harbor created thereby. Thesestatements relate to future events or the Company's future financialperformance and involve known and unknown risks, uncertainties and otherfactors that may cause the actual results, levels of activity, performance orachievements of the Company or its industry to be materially different fromthose expressed or implied by any forward-looking statements. In some cases,forward-looking statements can be identified by terminology such as "may,""will," "could," "would," "should," "expect," "plan," "anticipate," "intend,""believe," "estimate," "predict," "potential" or other comparable terminology.The Company has based these forward-looking statements on its currentexpectations, assumptions, estimates and projections. While the Companybelieves these expectations, assumptions, estimates and projections arereasonable, such forward-looking statements are only predictions and involveknown and unknown risks and uncertainties, many of which are beyond theCompany's control. These and other important factors, including thosediscussed under "Risk Factors" in the Company's Form 10-K for the year endedJune 28, 2008, as well as the Company's subsequent filings with the Securitiesand Exchange Commiss
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close